Successful induction and consolidation therapy of acute myeloid leukaemia in a renal allograft recipient.
Immunosuppressed organ transplant recipients have a markedly increased risk of neoplasia. Among these malignancies acute myeloid leukaemia (AML) is rare. However, until now no case of successful chemotherapy has been reported. We present a 39-year-old male patient who developed AML (FAB M4 Eo) 4 years after renal transplantation and achieved a stable complete remission after induction therapy with standard dose cytarabine and daunorubicin. Remission duration is now 11 months. At present the transplant is functioning well after two additional courses of consolidation chemotherapy with high-dose cytarabine combined with mitoxantrone and idarubicine respectively. Cyclosporin A was given during all cycles of chemotherapy. We conclude that intensive chemotherapy in patients with AML following renal transplantation in good performance status is feasible.
Gorschlüter
M
M
Department of General Internal Medicine, University of Bonn, Germany.
Glasmacher
A
A
Risse
F
F
Klein
B
B
Klehr
H U
HU
Mezger
J
J
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D006801:Humans; D015255:Idarubicin / Q000627:therapeutic use; D007165:Immunosuppression Therapy / Q000009:adverse effects*; D016030:Kidney Transplantation / Q000009:adverse effects*; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000209:etiology; D008297:Male; D008942:Mitoxantrone / Q000627:therapeutic use; D014184:Transplantation, Homologous
D008942:Mitoxantrone; D015255:Idarubicin